Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
VANCOUVER, British Columbia and WARMINSTER, Pa., Aug. 01, 2017 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, August 3, 2017 at 1:30 PM Pacific Time (4:30 PM Eastern Time) to discuss second quarter 2017 financial results and provide a corporate update.
To access the conference call, a live webcast of the call can be accessed through the Investor section of Arbutus' website at www.arbutusbio.com. Or, alternatively, to access the conference call, please dial 1-914-495-8556 or 1-866-393-1607.
An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling 1-404-537-3406 or 1-855-859-2056 and referencing conference ID 63313299.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, and has facilities in Warminster, PA. For more information, visit www.arbutusbio.com.
Contact Information Investors Adam Cutler Senior Vice President, Corporate Affairs Phone: 604-419-3200 Email: [email protected] Tiffany Tolmie Manager, Investor Relations Phone: 604-419-3200 Email: [email protected] Media David Schull Russo Partners Phone: 858-717-2310 Email: [email protected]
